Coronary disease & ACSDiagnostic or prognostic study
Takotsubo syndrome diagnosis: the biomarker-based BioTAK score
- Diagnostic score development and external validation study
- overlapping registries
- machine learning-guided feature selection
- logistic regression
Authors' conclusion
TTS is characterized by a distinct biomarker profile reflecting pathophysiological differences from ACS. The non-subjective biomarker-based BioTAK score can support the early identification of TTS, help streamline diagnostic pathways, and might reduce potentially avoidable invasive procedures in patients presenting with suspected ACS.
Study context
- Population
- Patients with acute coronary syndrome (ACS) or TTS from overlapping registries, biomarkers measured before invasive coronary angiography
- Participants
- 3,615 patients
- Comparison
- BioTAK score for differentiating TTS from ACS before invasive coronary angiography
- Developmentn = 1,823
- External validationn = 1,792
- Outcome
- Discrimination of TTS from ACS (AUC) of the biomarker-based BioTAK score
Performance
As reported in the abstract
Discrimination between TTS and ACS (AUC)
| Test or model | AUC |
|---|---|
| Development | .97 (95% CI .95-.98) |
| External validation | .93 (95% CI .90-.96) |
Further findings
Stratification by predefined rule-in and rule-out thresholds
- Patients stratified to a likely diagnosis prior to invasive coronary angiography (ICA)
- almost 90%
Original publication
Takotsubo syndrome diagnosis: the biomarker-based BioTAK score. Eur Heart J. Published 31 August 2026. doi:10.1093/eurheartj/ehag597
Summarised from the published abstract; every number is checked against it